
USA - NASDAQ:KTOV -
The current stock price of KTOV is 4.17 null. In the past month the price increased by 2.71%. In the past year, price decreased by -45.12%.
Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.
Kitov Pharma Ltd
ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD
TEL AVIV L3 6701101
CEO: Isaac Israel
Phone: 972-3933-3121
Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.
The current stock price of KTOV is 4.17 null. The price increased by 2.21% in the last trading session.
KTOV does not pay a dividend.
KTOV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
KTOV stock is listed on the Nasdaq exchange.
Kitov Pharma Ltd (KTOV) has a market capitalization of 65.57M null. This makes KTOV a Micro Cap stock.
You can find the ownership structure of Kitov Pharma Ltd (KTOV) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to KTOV. When comparing the yearly performance of all stocks, KTOV is a bad performer in the overall market: 94.86% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to KTOV. Both the profitability and financial health of KTOV have multiple concerns.
Over the last trailing twelve months KTOV reported a non-GAAP Earnings per Share(EPS) of -3. The EPS increased by 18.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -585% | ||
| ROA | -6.82% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |